Edition:
United States

Abiomed Inc (ABMD.O)

ABMD.O on Nasdaq

134.92USD
2:17pm EDT
Change (% chg)

$0.18 (+0.13%)
Prev Close
$134.74
Open
$135.00
Day's High
$135.44
Day's Low
$134.31
Volume
254,248
Avg. Vol
354,125
52-wk High
$137.00
52-wk Low
$95.14

Latest Key Developments (Source: Significant Developments)

Abiomed Impella 2.5 and Impella 5.0 heart pumps receive regulatory approval from Japan Ministry of Health, Labor & Welfare
Tuesday, 27 Sep 2016 07:53am EDT 

Abiomed Inc : Abiomed Impella 2.5 and Impella 5.0 heart pumps receive regulatory approval from Japan Ministry of Health, Labor & Welfare . Co planning future discussions with PMDA relating to potential regulatory reviews of Impella CP and Impella RP later this fiscal year . Plans to start supporting patients in Japan during Q4 of FY '17 . Company will conduct a post-market surveillance on Impella usage .Says does not expect material revenue until FY'18.  Full Article

Abiomed reports Q1 gaap earnings per share of $0.29
Thursday, 28 Jul 2016 07:00am EDT 

Abiomed Inc : Is maintaining its fiscal year guidance for gaap operating margin in range of 18% to 20% . Fy2017 revenue view $439.5 million -- Thomson Reuters I/B/E/S . Abiomed announces q1 fy 2017 revenue of $103.0 million, up 40% over prior year . Q1 gaap earnings per share $0.29 . Q1 earnings per share view $0.23 -- Thomson Reuters I/B/E/S . Q1 revenue $103 million versus i/b/e/s view $97.2 million .Is increasing lower end of its fiscal year 2017 revenue guidance with new range of $435 million to $445 million.  Full Article

Abiomed reports Q1 GAAP earnings per share of $0.29
Thursday, 28 Jul 2016 07:00am EDT 

Abiomed Inc : Abiomed announces q1 fy 2017 revenue of $103.0 million, up 40% over prior year . Q1 gaap earnings per share $0.29 . Q1 revenue $103 million versus i/b/e/s view $97.2 million . Q1 earnings per share view $0.23 -- Thomson Reuters I/B/E/S . Abiomed inc says increasing lower end of its fiscal year 2017 revenue guidance with new range of $435 million to $445 million . Abiomed inc says maintaining its fiscal year guidance for gaap operating margin in range of 18% to 20% .Fy2017 revenue view $439.5 million -- Thomson Reuters I/B/E/S.  Full Article

Abiomed Inc gives FY 2017 revenue guidance
Tuesday, 3 May 2016 07:00am EDT 

Abiomed Inc:Gives FY 2017 guidance for total revenues to be in the range of $430 million to $445 million.  Full Article

Abiomed Inc gives Q3 2016 revenue guidance
Monday, 11 Jan 2016 04:00pm EST 

Abiomed Inc:Says reported preliminary unaudited Q3 2016 revenue of approximately $85.8 million.  Full Article

Abiomed announces FDA Submission of Impella 2.5, Impella CP & Impella 5.0/LD Pre-Market Approval Supplements
Monday, 17 Aug 2015 08:00am EDT 

Abiomed Inc:Says that it has submitted U.S Food & Drug Administration (FDA) pre-market approval (PMA) supplemental submissions requesting to expand Impella 2.5 PMA approval to all of the Impella family of devices (Impella 2.5, Impella CP and Impella 5.0/LD).  Full Article

Abiomed Inc announces corporate partnership with Fenway Park
Tuesday, 11 Aug 2015 01:00pm EDT 

Abiomed Inc:Entered into a corporate partnership with Fenway Park and will be bringing its Impella Mobile Learning Lab to the historic baseball stadium tomorrow.  Full Article

Abiomed Inc raises FY 2016 revenue guidance
Tuesday, 4 Aug 2015 07:00am EDT 

Abiomed Inc:Raises FY 2016 guidance for total revenue to be in the range of $300-$310 million.FY 2016 revenue of $292 million - Thomson Reuters I/B/E/S.  Full Article

More From Around the Web

BRIEF-Abiomed says enrolled first patient in FDA approved prospective feasibility study

* Abiomed - enrollment of first patient in fda approved prospective feasibility study, STEMI door to unloading with Impella CP system in acute myocardial infarction